Mark Platt assumes role as full-time President and CEO of Makana Therapeutics, a subsidiary of Recombinetics Makana and Recombinetics merged their operations in 2020 to facilitate the mission of helping solve the nation’s organ donor crisis by advancing xenotransplantation technology EAGAN, MN — January 18, 2022 — Recombinetics™ Inc., a [...]
About Adam DaviesThis author has not yet filled in any details.
So far Adam Davies has created 124 blog entries.
Makana Statement about Transplant of Gal-Knockout Pig Kidney into a Recently Deceased Human with an Intact Circulation
MIAMI (October 25, 2021) – We at Makana Therapeutics and Recombinetics would like to take this opportunity to congratulate our good friend and colleague Dr. Robert Montgomery and his team at N.Y.U. Langone for their recent breakthrough experiment transplanting a Gal-knockout pig kidney into a recently deceased human with an [...]
A winning solution to KidneyX’s inaugural prize competition, the Artificial Kidney Prize – Phase 1, came from Makana Therapeutics. This submission is titled, “Xenotransplantation: A treatment for Kidney Failure.”
EAGAN, Minn., Sept. 15, 2021 /PRNewswire/ -- Makana Therapeutics today received a $650,000 KidneyX Artificial Kidney Prize for their work to increase the supply of kidney donor organs through pig-to-human xenotransplants. Xenotransplantation is the process of transplanting organs or tissues between members of different species into humans, thus addressing the [...]
The FDA greenlights α-Gal allergy-safe meat, but its makers have organs for transplants in their sights. The first genetically engineered pig products could soon be coming to a dinner plate—or pharmacy—near you. Late last year, the US Food and Drug Administration (FDA) authorizeda facility in northern Iowa to raise hogs [...]
Recombinetics Inc., a leading gene editing company with platform technology applied to biomedicine and animal agriculture, today announced a first-of-its-kind study to improve outcomes for patients diagnosed with a rare disease known as Tuberous Sclerosis Complex (TSC). Surrogen, a subsidiary of Recombinetics Inc., is focused on developing large animal models [...]
Surrogen’s Vice President of Research & Development, Dr. Adrienne Watson, PhD, is featured in GeneWorx Capital Webinar discussing the "Power of the Pig" in finding the next generation of Cancer Therapies.
EAGAN, Minn., Oct. 14, 2020 /PRNewswire/ -- Acceligen, the leading Precision Breeding company for food animals, today announced that they are opening a new office in Aracatuba, Sao Paolo State to better meet the needs for commercialization of their traits to improve cattle, swine, and fish in Brazil.
EAGAN, Minn., Sept. 24, 2020 /PRNewswire/ -- Acceligen, a Recombinetics Inc. company, today announced that it received a grant from the Bill & Melinda Gates Foundation to develop bovine genetics optimized with traits desirable to smallholder dairy farmers. The breeding program will contribute to more sustainable production by using traits [...]
A grant made possible by the Bill and Melinda Gates Foundation is meant to develop bovine genetics optimized with traits desirable to smallholder dairy farmers. Acceligen, a recognized global leader in the development, deployment, and commercialization of precision animal breeding technologies. They are launching a program for precision crossbreeding of [...]